422
Views
14
CrossRef citations to date
0
Altmetric
Urology

Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: Evaluation of cardiovascular events in a randomized trial

, , , , , , , , & show all
Pages 346-353 | Received 18 Feb 2011, Accepted 28 Apr 2011, Published online: 31 May 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Jason F Lester & Malcolm D Mason. (2015) Cardiovascular effects of hormone therapy for prostate cancer. Drug, Healthcare and Patient Safety 7, pages 129-138.
Read now
Rafal Turo, Michal Smolski, Rachel Esler, Magda L. Kujawa, Stephen J. Bromage, Neil Oakley, Adebanji Adeyoju, Stephen C. W. Brown, Richard Brough, Andrew Sinclair & Gerald N. Collins. (2014) Diethylstilboestrol for the treatment of prostate cancer: past, present and future. Scandinavian Journal of Urology 48:1, pages 4-14.
Read now

Articles from other publishers (12)

K. M. Nyushko, V. M. Perepukhov & B. Ya. Alekseev. (2021) Diferelin® as an effective chemical castration agent for patients with prostate cancer. Cancer Urology 16:4, pages 191-196.
Crossref
Patrick Davey & Mike G. Kirby. (2020) Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. World Journal of Urology 39:2, pages 307-315.
Crossref
Hendrik Van Poppel & Per‐Anders Abrahamsson. (2020) Considerations for the use of gonadotropin‐releasing hormone agonists and antagonists in patients with prostate cancer. International Journal of Urology 27:10, pages 830-837.
Crossref
Natividad R. Fuentes, Eunjoo Kim, Yang-Yi Fan & Robert S. Chapkin. (2018) Omega-3 fatty acids, membrane remodeling and cancer prevention. Molecular Aspects of Medicine 64, pages 79-91.
Crossref
Sivaporn Sivasinprasasn, Krekwit Shinlapawittayatorn, Siriporn C. Chattipakorn & Nipon Chattipakorn. (2016) Estrogenic Impact on Cardiac Ischemic/Reperfusion Injury. Journal of Cardiovascular Translational Research 9:1, pages 23-39.
Crossref
Daan Joost De Maeseneer, Charles Van Praet, Nicolaas Lumen & Sylvie Rottey. (2015) Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations. Urologic Oncology: Seminars and Original Investigations 33:7, pages 310-321.
Crossref
Louis J Gooren, Katrien Wierckx & Erik J Giltay. (2014) Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern. European Journal of Endocrinology 170:6, pages 809-819.
Crossref
Nirupama D Mitikiri, Emily S Reese, Arif Hussain, Eberechukwu Onukwugha, Daryl Pritchard, Robert Dubois & C Daniel Mullins. (2013) The emerging relevance of heterogeneity of treatment effect in clinical care: a study using stage IV prostate cancer as a model. Journal of Comparative Effectiveness Research 2:6, pages 605-618.
Crossref
Ruth E Langley, Fay H Cafferty, Abdulla A Alhasso, Stuart D Rosen, Subramanian Kanaga Sundaram, Suzanne C Freeman, Philip Pollock, Rachel C Jinks, Ian F Godsland, Roger Kockelbergh, Noel W Clarke, Howard G Kynaston, Mahesh KB Parmar & Paul D Abel. (2013) Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). The Lancet Oncology 14:4, pages 306-316.
Crossref
S. Basaria, M. N. Davda, T. G. Travison, J. Ulloor, R. Singh & S. Bhasin. (2012) Risk Factors Associated With Cardiovascular Events During Testosterone Administration in Older Men With Mobility Limitation. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 68:2, pages 153-160.
Crossref
C. Leclercq, O. Bouchot, A.-R. Azzouzi, F. Joly, N. Miaadi, C. Pfister, S. Vincendeau & R. de Crevoisier. (2012) Hormonothérapie et risque cardiaque dans le traitement des cancers prostatiques. Progrès en Urologie 22, pages S48-S54.
Crossref
J. Rohayem & S. Kliesch. (2012) Antiandrogene Therapie des ProstatakarzinomsAndrogen deprivation therapy in prostate cancer. Der Urologe 51:4, pages 557-566.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.